Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Menopausal disorders (Estradiol with dydrogesterone - Menopausal disorders)

Records returned : 35 (on 29 May 2025 at 11:09:37). Return to search results for ' Menopausal disorders '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Femoston tablets - 1st line for women requiring sequential combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Femoston Conti - 1st line for women requiring continuous combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Preferred
Elleste Solo tablets - 1st line
 
Links :
Indication :
Status :
Green
Formulations :
  • Patches
Restrictions / Comments:

Important
Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)
 
Links :
Indication :
Status :
Green
Formulations :
  • Spray
Restrictions / Comments:

Important
Lenzetto spray. Caution with higher than licensed doses. Max supply of 20 containers per year to stay within licensed dose.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Gel
Restrictions / Comments:

Important
Oestrogel is the preferred gel option. Sandrena is an alternative option.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.
 
Links :
Indication :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
Bijuve capsules - 1st line for women requiring continuous combined therapy.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Prescribe generically
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Femseven Conti patches - less preferred. Only use in the event of product shortages.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Novofem tablets - Only use if there are product shortages with Elleste Duet
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Patches
Restrictions / Comments:

Important
Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Trisequens tablets - consider changing to newer, 1st or 2nd line options.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important

Off-label use.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Intrauterine device (progestogen only)
Restrictions / Comments:

Important

Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf

  • Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Tablets
Restrictions / Comments:

Important

Off-label use.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important

Off-label use.

Off-label use

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Capsules
Restrictions / Comments:

Important
Preferred
Prescribe generically. Micronised progesterone oral capsules.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Pessaries
Restrictions / Comments:

Important

Progesterone pessaries have not been agreed for use as endometrial protection.

 
Links :
Indication :
Status :
Green (see narrative)
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important

Off-label use.

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Recommend switching to a newer, lower risk formulation.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Modified release tablets
Restrictions / Comments:

Important
Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Guidelines SPC
NFD1
Un
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
35.
Drug:
Indication :
Status :
Restrictions / Comments:

Important

Safety Notice:

Unopposed oestrogen replacement is associated with a significant increase in the risk of endometrial hyperplasia that is both dose and duration dependent with exposure between one and three years. Non-hysterectomised women require progestogen administered for 12–14 days in a sequential regimen and daily in a continuous combined regimen to minimise the risk of endometrial hyperplasia and endometrial cancer associated with unopposed estrogen exposure. Healthcare Professionals should be aware of BMS guidance when prescribing HRT.

High dose oestrogen - The Surrey Heartlands Area Prescribing Committee does not support prescribing of HRT with oestrogen doses above those specified in the license. This is because there is insufficient evidence of efficacy or safety to support this. Specialists may prescribe higher doses of oestrogens with the appropriate opposing progestogen doses but need to retain prescribing responsibility and not transfer prescribing to primary care. Where specialists take the responsibility of initiating higher doses of oestrogens, they should do so for a limited period of time and retain prescribing responsibility for both oestrogens and associated progestogens. They should be aware of the BMS guidance with regards to requiring increased doses of progestogens to ensure adequate endometrial protection.

 
Links :